<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
81927-201-01
</NDCCode>
<PackageDescription>
140 mL in 1 BOTTLE (81927-201-01)
</PackageDescription>
<NDC11Code>
81927-0201-01
</NDC11Code>
<ProductNDC>
81927-201
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Imkeldi
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Imatinib Oral
</NonProprietaryName>
<DosageFormName>
SOLUTION
</DosageFormName>
<RouteName>
ORAL
</RouteName>
<StartMarketingDate>
20241219
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA219097
</ApplicationNumber>
<LabelerName>
Shorla Oncology Inc.,
</LabelerName>
<SubstanceName>
IMATINIB MESYLATE
</SubstanceName>
<StrengthNumber>
80
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2024-12-20
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20241219
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>